PALI-2108 demonstrated to be safe and well tolerated with no serious adverse events (SAEs) Extended half-life and local bioactivation support convenient once-daily dosing in ulcer ...

Topline results from CATT1 Phase 3 trial expected in second half of 2026. HIGH POINT, NC, USA I August 07, 2025 I vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceuti ...

BERKELEY HEIGHTS, NJ, USA I August 07, 2025 I CorMedix Inc. (“CorMedix”) (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing ...

ROCKVILLE, MD, USA I August 7, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) today announced it will initiate a pivotal Phase IIb/III clinical trial for ...

Funding will advance Strand’s pipeline and mission to bring targeted, next-generation mRNA therapies to patients ...

TORONTO, Canada I August 07, 2025 I ProteinQure, a leader in computational protein drug discovery, today announced it has received regulatory clearance from ...

Kaken will also provide support for the ALPHA-ORBIT Phase 3 trial in Japan, be responsible for regulatory submissions in Japan, and will reimburse Astria for a portion of the costs of the navenibart ...

SAN FRANCISCO, CA, USA I August 06, 2025 I Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in ECLIPSE 3. All ...

INCHEON, South Korea I August 6, 2025 I Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication ...

AHMEDABAD, India I August 7, 2025 I Intas Pharmaceuticals in collaboration with its global subsidiaries operating under the Accord brand, has solidified ...